European Commission grants conditional clearance to Remdesivir – Reuters
|The European Commission announced on Friday that it had granted conditional clearance for the use of Gilead Sciences' antiviral Remdesivir in coronavirus treatment, as reported by Reuters.
This decision came after the European Medicines Agency's "rolling review" that started at the end of April.
Earlier in the week, the Commission said it was in negotiations with Gilead to purchase enough doses for the member EU countries.
Meanwhile, "under the authorization, Remdesivir is indicated for the treatment of COVID-19 in adults and adolescents with pneumonia requiring supplemental oxygen," Gilead Sciences said in a statement. "Conditional marketing authorization in Europe for Veklury (Remdesivir) is initially valid for one year."
Market reaction
This headline doesn't seem to be having a significant impact on market sentiment. As of writing, the Euro Stoxx 50 Index was down 0.7% on a daily basis at 3,297 points.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.